Host: Donna Ryan, MD Guest: Juan Pablo Frías, MD Dropping 15% or more of body weight has a greater disease-modifying effect than any other glucose-lowering intervention. Join Drs. Donna Ryan and Juan Pablo Frias as they discuss implementing an upst

Host: Cem Akin, MD, PhD Guest: Jason Gotlib, MD, MS It could take up to 7 years for a patient to be accurately diagnosed with systemic mastocytosis. Drs. Jason Gotlib and Cem Akin take us through the guidelines, diagnostic criteria, signs and sympt

Host: John Kitchens, MD Guest: SriniVas R. Sadda, MD Whether you’re a medical or surgical retina specialist, the port delivery system (PDS) is a practice-changing treatment modality. How can you smoothly incorporate continuous anti-VEGF delivery te

Host: Charles P. Vega, MD Guest: Rajeev Raghavan, MD, M.Ed, FASN Clinicians have a critical need for up-to-date knowledge related to anemia of CKD. Provide better care for your patients by learning about the importance of assessing and treating whi

Host: Carl Danzig, MD Guest: Arshad M. Khanani, MD, MA With the availability of multiple novel treatment options, how do we decide which is best for each patient with neovascular age-related macular degeneration? Join Dr. Arshad Khanani and Dr. Car

Host: Ileana L. Piña, MD, MPH, FAHA, FACC Guest: Patrick Rossignol, MD, PhD In heart failure, the use of MRAs is often delayed despite being a crucial part of medical therapy. The evidence is clear that clinical inertia and the suboptimal use of th

Host: Guillermo Garcia-Manero, MD Guest: Rami Komrokji, MD Lower-risk MDS is an acquired bone marrow disorder that manifests with symptomatic anemia. Over time, many of these patients become dependent on red cell transfusions. Erythropoiesis-stimul

Host: Ayse Tuba Kendi, MD Guest: A. Oliver Sartor, MD Prostate-specific membrane antigen (PSMA) is highly expressed on prostate cancer (PC) cells and can be detected in tumors using positron emission tomography imaging. Even though clinical feature

Host: Rami Komrokji, MD Guest: Michael R. Savona, MD Guest: Jamile Shammo, MD, FASCP, FACP Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid neoplasms associated with cytopenias, suboptimal production of mature erythrocytes, an

Guest: Andrew M. Brunner, MD Myelodysplastic syndrome (MDS) is a group of myeloid malignancies characterized by ineffective hematopoiesis, inflammation, and immune dysregulation in the setting of multiple genomic disruptions. Disease burdens associat